Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes.
暂无分享,去创建一个
[1] F. McAlister,et al. Antihypertensive medication prescribing in 27,822 elderly Canadians with diabetes over the past decade. , 2006, Diabetes care.
[2] L. Nalysnyk,et al. Discontinuation of Antihypertensive Drugs Due to Adverse Events: A Systematic Review and Meta‐analysis , 2001, Pharmacotherapy.
[3] Ames,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[4] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[5] S. Kaplan,et al. Improving the Reliability of Physician Performance Assessment: Identifying the “Physician Effect” on Quality and Creating Composite Measures , 2009, Medical care.
[6] S. Ellenberg. Surrogate end points in clinical trials. , 1991, BMJ.
[7] J. Dora,et al. Standards of Medical Care in Diabetes—2008 , 2008, Diabetes Care.
[8] D J Reda,et al. Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo , 1993 .
[9] Luni Chen,et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.
[10] W. Alexander,et al. Contraindications to the use of metformin , 2003, BMJ : British Medical Journal.
[11] C. Lewis,et al. A summary of the effects of antihypertensive medications on measured blood pressure. , 2005, American journal of hypertension.
[12] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[13] T. Lumley,et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. , 2002, Archives of internal medicine.
[14] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[15] J. Henney. Infant Pneumococcal Vaccine , 2000 .
[16] N J Wald,et al. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.
[17] S. Nightingale,et al. From the Food and Drug administration. , 1990, JAMA.
[18] Jeffrey B. Gross,et al. Timing of New Black Box Warnings and Withdrawals for Prescription Medications , 2003 .
[19] N J Wald,et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003, BMJ : British Medical Journal.
[20] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[21] Minge Xie,et al. Assessing quality of diabetes care by measuring longitudinal changes in hemoglobin A1c in the Veterans Health Administration. , 2005, Health services research.
[22] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[23] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[24] M. Safford,et al. Performance status of health care facilities changes with risk adjustment of HbA1c. , 2000, Diabetes care.
[25] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.
[26] R. Arora,et al. The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. , 2007, American heart journal.
[27] D. Asch,et al. Racial Profiling: The Unintended Consequences of Coronary Artery Bypass Graft Report Cards , 2005, Circulation.
[28] Thomas Lumley,et al. Analysis of Complex Survey Samples , 2004 .
[29] R. Hayward,et al. Beyond the Randomized Clinical Trial the Role of Effectiveness Studies in Evaluating Cardiovascular Therapies the Achilles' Heel of Rcts Key Issues in Outcomes Research , 2022 .
[30] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[31] H. Krumholz,et al. Redefining quality--implications of recent clinical trials. , 2008, The New England journal of medicine.
[32] Rodney A Hayward,et al. Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem , 2006, Annals of Internal Medicine.
[33] F. Nuttall,et al. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): Results of the feasibility trial , 1995, Diabetes Care.
[34] R. Hayward,et al. Avoiding pitfalls in chronic disease quality measurement: a case for the next generation of technical quality measures. , 2001, The American journal of managed care.
[35] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[36] Rodney A Hayward,et al. Building a Better Quality Measure: Are Some Patients With ‘Poor Quality’ Actually Getting Good Care? , 2003, Medical care.